

---

Administrative Report

Clinical Practice Guidelines for Management of Sarcoma  
– Series 1

---



21<sup>st</sup> March 2022

## Scope of the administrative report

This administrative report refers to the development of Clinical Practice Guidelines for Management of Sarcoma (Series 1).

## Table of Contents

|  |   |
|--|---|
| Preamble                                   | 3 |
| Responsible Organisation                   | 3 |
| Funding                                    | 3 |
| Multidisciplinary working party            | 3 |
| Guidelines working party membership        | 4 |
| Consumer Involvement                       | 4 |
| Declaration of conflict of interest        | 5 |
| Funding                                    | 5 |
| Meetings                                   | 5 |
| Training for working party members         | 6 |
| Consensus-based recommendations            | 6 |
| Public consultation                        | 7 |
| Appendix 1 - Working Group Party Members   |   |
| Appendix 2 - Conflict of interest Register |   |

## Preamble

As the leading research organisation in sarcoma in Australia and New Zealand, the Australia and New Zealand Sarcoma Association (ANZSA) is dedicated to improving the outcome for patients with sarcoma through awareness, education, and research. ANZSA fosters effective collaborations across medical and psychosocial multidisciplinary teams (MDT), comprising specialist health professionals (including pathologists, radiologists, surgeons, radiation oncologists, medical oncologists, paediatric oncologists, and allied health) working together to identify the best management and care of patients with sarcoma and related tumours. Pivotal to this goal is the development and dissemination of clinical practice guidelines based on systematic review to evaluate evidence for best management of adult and paediatric patients with sarcoma. The previous Australian clinical practice guidelines for the management of adult onset sarcoma were published in 2013. This current guidelines development process was commenced at the end of 2020 with full support from the board and the scientific advisory committee of ANZSA. The working party uses evidence-based methodologies to develop guideline recommendations in accordance with the National Health and Medical Research Council (NHMRC) standard. (<https://www.nhmrc.gov.au/guidelinesforguidelines>).

## Responsible Organisation

ANZSA is responsible for developing and dissemination of the guidelines. ANZSA is a not for profit organisation and the operations are funded by Cancer Australia grant. Its vision is to improve early diagnosis, treatment options, outcomes, and quality of life of patients with sarcomas and related tumours through outstanding national and international, basic, translational, clinical, and supportive care research and clinical trials.

## Funding

The guidelines development is solely funded by ANZSA to cover guideline development training (GRADE training and The International Guideline Credentialing and Certification (INGUIDE) Program), publication, and dissemination. There is no commercial support.

Apart from the project manager, members of the working party volunteer their time to participate in the guideline development.

## Multidisciplinary working party

The management of sarcoma is complex and involves the input of a multidisciplinary team to achieve the optimal outcome. Therefore, it was decided that the working party should include experts from multidisciplinary medical speciality such as radiation oncology, medical oncology, orthopaedic surgery, surgical oncology, paediatric/adolescent young adult oncology, pathology as well as end-users such as a general oncology, general practice, psychology, and consumer. A clinical librarian with expertise in systematic review has assisted with literature search and the systematic management software system Covidence.

A call for expression of interest with the terms of reference was sent to members of scientific advisory committee and the consumer advisory party of ANZSA on the 14<sup>th</sup> August 2020. The guideline chair and ANZSA CEO reviewed the applications to ensure the working party consists of multidisciplinary group with variation in areas of expertise in sarcoma management, geographic region, gender, and practice setting. To foster the next generation of medical specialist, advanced trainees in radiation oncology, medical oncology, surgical oncology, and orthopaedic surgery were invited to participate in the systematic review and guidelines development.

At the first guideline working party meeting on 7th December 2020, the members discussed and voted on the theme of three broad topics (specialised sarcoma care, retroperitoneal sarcoma, paediatric/AYA sarcoma). The working party was then divided into three smaller working groups each with a topic lead. Each topic working group focused their attention on the specific topics and the agreed research questions. The smaller topic working groups worked on the systematic reviews and the initial draft recommendations before presenting to the whole working group for further feedback and discussion. Despite the relatively large size of the working party, all members worked efficiently together in their smaller topic working groups and made valuable contributions in the areas of their expertise.

## Guidelines working party membership

Please see Appendix 1. Working Party Members for the full list of the Sarcoma Guidelines Working Party Members.

## Consumer Involvement

A call for expression of interest with the terms of reference was sent to all consumer members of the ANZSA Consumer Advisory Party (CAP) on the 14<sup>th</sup> August 2020. The consumers are volunteers with the purpose to assist in research and academic endeavours for ANZSA. The CAP has a Terms of Reference that serves as a policy for engagement and support of consumer members. Two consumers accepted a role as working group members in the guideline working group.

Both consumers were involved in the initial guideline development process and participated in initial discussions at end of 2020 to determine the focus of the guideline questions. They were also invited to take part any educational courses for example GRADE training and Covidence training. They were included in all communications with the opportunity to contribute at any stage. Furthermore, they were offered support in terms of further explanation and discussion of the more technical aspects of the guideline development process as needed. Both were involved in the final evaluation of the guideline recommendations and the plain English summary.

A third consumer (independent of the guideline development process) will also take part as an independent reviewer of the draft guidelines.

During the public consultation period, the key sarcoma consumer advocacy groups are individually invited to review and comment.

## Declaration of conflict of interest

To ensure a guideline's recommendations are objective and unbiased all members are asked to declare their interests. The term of reference for guidelines working party clearly stated the need to declare any potential conflict of interest at the beginning of the membership and during the course of the membership should one arise. A declaration form is completed by each member at the beginning of the membership.

Throughout the guideline development, members are reminded of their obligation to consider any interest that may have arisen since the last meeting or with any agenda items. No potential competing interests have been identified that required a formal management plan. Please see Appendix 2 for the Conflict of Interest Register.

## Funding

The ANZSA board approved a budget of \$27,000 for guideline development in 2020 to include training, software and project officer's salary. ANZSA has not sought any commercial funding for this guideline development.

## Meetings

Each meeting is chaired by the chair of the guidelines working party and relevant members are invited to join. The agenda and relevant reading materials are provided at least one week prior to each meeting. The minutes of the meeting and follow up reading materials are provided to the working party within 2 weeks. The initial plan was to hold day-long face to face meetings to appraise the systematic review, and vote on the final evidence summary and recommendations. Due to Covid 19 pandemic, these meetings were convened as shorter virtual meetings (meeting dates to discuss draft guideline recommendations are listed below):

9<sup>th</sup> February 2022 – Topic 1 group meeting  
1<sup>st</sup> March 2022 – Topic 3 group meeting  
7<sup>th</sup> March 2022– Topic 1 group meeting

In addition, the chair and the project officer meet virtually every two weeks to manage the progress of the guidelines development. The chair and the project manager have also met with more junior members of the working party individually to provide guidance and support.

## Training for working party members

A series of educational courses were provided to the working party member to support their understanding of the systematic review and guidelines development.

**GRADE Workshop**, presented by Associate Prof Zachary Munn, Director JBI Adelaide GRADE Centre, Joanna Briggs Institute

Date: 24<sup>th</sup> November 2020

Attendees: Angela Hong, Denise Caruso, Jasmine Mar, Lisa Orme, Fiona Maclean, Joshua McDonough, Marianne Phillips, Smaro Lazarakis, Jeremy Lewin, Natacha Omer, Susie Bae, Elizabeth Connolly, Vivek Bhadri, Peter Lee

*\*Workshop recording and materials were made available to all members of the working party after the workshop*

### **Covidence Training Webinar**

Host: Covidence Community Manager Nancy Owens

Attendees: Angela Hong, Denise Caruso, Jasmine Mar, Peter Grimison, Fiona Maclean, Anna Lawless, Marianne Phillips, Smaro Lazarakis

*\*Workshop recording and materials were made available to all members of the working party after the webinar*

**The International Guideline Credentialing and Certification (INGUIDE) Program** by the Guidelines International Network and McMaster University

Date: Self-paced learning available from 21<sup>st</sup> October 2021 onwards

Attendees: Angela Hong, Jasmine Mar, Natacha Omer, Julie Cayrol

## Consensus-based recommendations

In order for working party members to appraise the evidence for each question, each is provided with:

- access to Covidence systematic management system which has all publications included in the title/abstract screening, full text screening, the Prisma diagram, the pdf of all publications that meet the inclusion criteria and the data extraction
- an excel file with evidence table, which summarises the systematic review and critical appraisal of all studies that meet the inclusion criteria
- final quality assessment (NHMRC Evidence Hierarchy, Newcastle-Ottawa Quality Assessment Form for Cohort Studies, Cochrane Collaboration's tool for assessing risk of bias for randomised trial) for each publication that meet the inclusion criteria
- a draft guideline with evidence summary, recommendations and practice points at prior to topic working party meeting

During each meeting, the chair provides an overall view of the NHMRC guidelines for guidelines development, the NHMRC grades of recommendations and the NHMRC evidence statement criteria. Each topic lead then presents the summary of the systematic review

including areas of weak evidence, the evidence summary, recommendations, and practice points. All members are invited to contribute, debate and vote during the meeting. The draft guidelines are revised after the meeting based on the discussion and circulated to each member of the topic working party as well as the whole guidelines working party for review and final approval. Any dissenting views are freely discussed among members until a final decision can be reached based on the best evidence available. Each recommendation and practice point are reached by majority vote provided by the working party.

## Independent review

The guidelines and recommendations are in the process of being assessed by at two reviewers (a surgical oncologist in NSW and a consumer from the WEHI Consumer Advisory Panel). The reviewers are independent of the guideline development process and will assess the guidelines using the AGREE II instrument. Both reviewers will complete a declaration of conflict of interest form. Comments provided by the independent reviewers will be presented for consideration by all members of the guidelines working party.

## Public consultation

The draft of the guidelines with its technical and administrative reports were released for publication consultation 13th April 2022 – 13th May 2022 (Extended to 27th May for professional bodies). ANZSA solicited comments from its members by direct email alert, social media and listing the draft guidelines on its website.

The following professional and consumer organisations have been identified as key stakeholders that will be involved in, or affected by, the implementation of the clinical recommendations of the guideline. Each organisation is individually invited to provide comments and will consider any necessary revisions after the public consultation period.

- Royal Australia and New Zealand College of Radiologists, Faculty of Radiation Oncology (RANZCR)
- Medical Oncology Group of Australia (MOGA)
- Royal Australasian College of Surgeons (RACS)
- Australia Orthopaedic Association (AOA)
- Clinical Oncology Society of Australia (COSA)
- Australia and New Zealand Children Haematology Oncology Group (ANZCHOG)
- Royal Australian College of General Practitioners (RACGP)
- Sock it to Sarcoma (Consumer organisation)
- Rainbows for Kate (Consumer organisation)
- Rare Cancers Consumer Group (Consumer organisation)
- Kicking Goals for Xav (Consumer organisation)

All comments will be considered by the chair and members of the topic working party. Changes will be made to the draft guidelines when it is considered as appropriate. A public consultation summary table listing each comment resulted in a change to the guidelines, or that the comment was considered but did not result in a change, and the reasons why it did

not will be kept. A de-identified version of the public consultation summary and the changes made to the guideline as a result will be published with the final guidelines.



## Appendix 1. Working Party Members

| Title  | First Name | Last Name    | Profession   | Representation   | Role in Guideline Development Process |
|--------|------------|--------------|--|--|---------------------------------------|
| Prof   | Angela     | Hong         | Radiation Oncologist   | Royal Prince Alfred Hospital/Chris O'Brien Lifehouse, NSW                  | Chair and Topic 1 Lead                |
| Dr     | Susie      | Bae          | Medical Oncologist   | Peter MacCallum Cancer Centre, VIC   | Working Group Member                  |
| Dr     | Vivek      | Bhadri       | AYA Medical Oncologist   | Royal Prince Alfred Hospital/Chris O'Brien Lifehouse, NSW                  | Working Group Member                  |
| Prof   | Richard    | Carey Smith  | Orthopaedic Surgeon  | Sir Charles Gairdner Hospital, WA  | Working Group Member                  |
| Dr     | Denise     | Caruso       | Chief Executive Officer  | Australia and New Zealand Sarcoma Association Limited                      | Working Group Member                  |
| Dr     | Julie      | Cayrol       | Paediatric and AYA Medical Oncologist                                  | Royal Children's Hospital, VIC   | Working Group Member                  |
| Prof   | Peter      | Choong       | Orthopaedic Surgeon  | St Vincent's Hospital Melbourne, VIC                                       | Working Group Member                  |
| Dr     | David      | Cocker       | Surgical Oncology Fellow   | Royal Prince Alfred Hospital, NSW  | Working Group Member                  |
| Dr     | Elizabeth  | Connolly     | Medical Oncologist/PhD Candidate                                       | Chris O'Brien Lifehouse, NSW   | Working Group Member                  |
| A/Prof | Jayesh     | Desai        | Medical Oncologist   | Peter MacCallum Cancer Centre, VIC   | Working Group Member                  |
| Ms     | Natalia    | Dewiyani     | Consumer Representative  | Consumer Representative, VIC   | Working Group Member                  |
| A/Prof | Peter      | Grimison     | Medical Oncologist   | Royal Prince Alfred Hospital/Chris O'Brien Lifehouse, NSW                  | Working Group Member                  |
| A/Prof | David      | Gyorki       | Surgical Oncologist  | Peter MacCallum Cancer Centre, VIC   | Topic 2 Lead & Working Group Member   |
| Dr     | Anna       | Lawless      | Radiation Oncology advanced trainee                                    | Chris O'Brien Lifehouse, NSW   | Working Group Member                  |
| Ms     | Smaro      | Lazarakis    | Clinical and Research Librarian  | Peter MacCallum Cancer Centre, VIC   | Clinical and Research Librarian       |
| Dr     | Peter      | Lee          | Surgical Oncologist  | Royal Prince Alfred Hospital, NSW  | Working Group Member                  |
| Dr     | Jeremy     | Lewin        | AYA Medical Oncologist   | Peter MacCallum Cancer Centre, VIC   | Working Group Member                  |
| Dr     | Tracy      | Lim          | Radiation Oncology advanced trainee                                    | Chris O'Brien Lifehouse, NSW   | Working Group Member                  |
| Dr     | Helen      | Lo           | Radiation Oncologist   | Port Macquarie Based Hospital  | Working Group Member                  |
| A/Prof | Fiona      | Maclean      | Pathologist  | Douglass Hanly Moir Pathology, NSW   | Working Group Member                  |
| Ms     | Jasmine    | Mar          | Research Coordinator   | Australia and New Zealand Sarcoma Association Limited (ANZSA)              | Project Officer                       |
| Dr     | Joshua     | McDonough    | Scientist  | The University of Adelaide, SA   | Working Group Member                  |
| Dr     | Wayne      | Nichols      | Paediatric and AYA Medical Oncologist                                  | Queensland Children's Hospital, QLD  | Working Group Member                  |
| Dr     | Natacha    | Omer         | Paediatric Medical Oncologist  | Queensland Children's Hospital, QLD  | Topic 3 Lead & Working Group Member   |
| Dr     | Lisa       | Orme         | Paediatric and AYA Medical Oncologist                                  | The Royal Children's Hospital Melbourne/Peter MacCallum Cancer Centre, VIC | Working Group Member                  |
| Dr     | Charlotte  | Payne        | General Practitioner   | General Practitioner, NSW  | Working Group Member                  |
| Dr     | Ganapathy  | Perianayagam | Orthopaedic Tumour Fellow  | Royal Prince Alfred Hospital, NSW  | Working Group Member                  |
| A/Prof | Marianne   | Phillips     | Paediatric and Adolescent Medical Oncologist/Palliative Care Physician | Perth Children's Hospital, WA  | Working Group Member                  |
| A/Prof | David      | Pryor        | Radiation Oncologist   | Princess Alexandra Hospital, QLD   | Working Group Member                  |
| Ms     | Ashika     | Ramamurthy   | Medical Student  | University of Sydney, NSW  | Working Group Member                  |
| Dr     | Richard    | Smith        | Surgical Oncologist  | Royal Adelaide Hospital, SA  | Working Group Member                  |
| A/Prof | Peter      | Steadman     | Orthopaedic Surgeon  | Princess Alexandra Hospital, QLD   | Working Group Member                  |
| Dr     | Abay       | Sundaram     | Orthopaedic Fellow   | Sir Charles Gairdner Hospital, WA  | Working Group Member                  |
| Dr     | Stephen    | Thompson     | Radiation Oncologist   | Prince of Wales Hospital, NSW  | Working Group Member                  |
| Ms     | Julijana   | Todorovic    | Consumer Representative  | Consumer Representative, VIC   | Working Group Member                  |
| Dr     | Cristina   | Vargas       | Pathologist  | Douglass Hanly Moir Pathology, NSW   | Working Group Member                  |
| Ms     | Jennifer   | Vu           | Medical Student  | University of Sydney, NSW  | Working Group Member                  |
| Dr     | Mark       | Winstanley   | Paediatric Medical Oncologist  | Starship Hospital, New Zealand   | Working Group Member                  |
| Dr     | Mei        | Zhang        | Research Assistant   | The University of Sydney, NSW  | Working Group Member                  |
| Dr     | Betty      | Zhang        | Medical Oncology Sarcoma Fellow  | Chris O'Brien Lifehouse, NSW   | Working Group Member                  |
| Dr     | Deborah    | Zhou         | Medical Oncology Sarcoma Fellow  | Chris O'Brien Lifehouse, NSW   | Working Group Member                  |

## Appendix 2. Conflict of Interest Register

| Title | First Name | Last Name   | Current employment and previous employment with continued financial interest  | Appointments e.g. trusteeships, Boards, committees & tribunals   | Membership of professional bodies, specialist societies, etc  | Direct or indirect payment of a financial or other benefits from Industry – provide specific details of payments or benefits in the past 12 months (incl date, company and reason for payment) | Other conflicts |
|-------|------------|-------------|---|--|---|--|-----------------|
| Dr    | Susie      | Bae         | Eastern Health, Peter MacCallum Cancer Centre, ANZSA  | Nil  | ASCO, ESMO, CTOS  | Nil  | Nil             |
| Dr    | Vivek      | Bhadri      | Chris O'Brien Lifehouse   | Nil  | ANZSA   | Nil  | Nil             |
| Prof  | Richard    | Carey Smith | Perth Orthopaedics + Sports Medcial Centre, Perth Bone Bank (PlusLife), Sir Charles Gardner Hospital, Perth Children's Hospital | Board member of ANZSA, AOA, WA AOA, Sock it to Sarcoma   | AOA, RACS, BOA, RCS (Eag), ANZSA  | Consutling - Zimmer Biomet, Lifehealthcare, DePuy Synthes, Ossis   |                 |
| Dr    | Denise     | Caruso      | Peter MacCallum Cancer Centre & CEO ANZSA   | Nil  | COSA, CTOS, ACTA, SARC  | Nil  | Nil             |
| Dr    | Julie      | Cayrol      | Monash Children's Hospital  | Nil  | SIOP (International society for paediatric oncology), COG (Children's Oncology Group), ANZSA, FRACP   | Nil  | Nil             |
| Prof  | Peter      | Choong      | University of Melbourne, St. Vincent's Hospital Melbourne   | Head of Department of Surgery Family Trust, Board Committee of AOA Research, Emeritus Board member MSK Australia, Multiple university committees | AOA, ANZSA, ISOLS, APMSTS, AAOS, AAHMS  | Consultancies with Stryker, Johnson and Johnson, Medacta   | Nil             |
| Dr    | David      | Coker       | Melanoma Institute Australia (MIA)<br>Royal Prince Alfred Hospital and Chris O'Brien Lifehouse                                  | Clinical Senior Lecturer, The University of Sydney   | Fellow of the Royal Australasian College of Surgeons<br>Member of General Surgeons Australia<br>Member of Australia and New Zealand Sarcoma Association | Nil  | Nil             |

|        |           |          |  |   |  |   |     |
|--------|-----------|----------|--|---|--|---|-----|
| Dr     | Elizabeth | Connolly | Chris O'Brien Lifehouse  | ANZSA ambulatory chemotherapy working group, RACP AMDAC- adult medicine division assessment committee | CTOS, ANZSA, MOGA  | Nil   | Nil |
| Dr     | Jayesh    | Desai    | Peter MacCallum Cancer Centre  | Chair, Board of Directors- Cancer Trials Australia, Director, ANZSA                                   | ANZSA, ASCO, ESMO, SARC  | Consulting: Pierre-Fabre, Novartis, Amgen, Eisai, Roche/Genentech, Beigene, Checkpoint therapeutics<br>Institutional Research Grants: Novartis, Roche/Genentech, BMS, Bionomics, GSK, Beigene   | Nil |
| Ms     | Natalia   | Dewiyani | Northern Health  | Committee member of Cancer Action Victoria  | ANZSA, Cancer Action Victoria  | Nil   | Nil |
| A/Prof | Peter     | Grimison | Chris O'Brien Lifehouse, Federal Department of Health - member, Pharmaceutical Benefits Advisory Committee | ANZSA - Scientific Advisory Committee   | Australia New Zealand Sarcoma Association, Royal Australasian College of Physicians, Medical Oncology Group of Australia | Direct: nil<br>Indirect:<br>1. Site principal investigator on trials conducted by Gilead (GS-2475); Tigermed (INC5HR01210); Pfizer (Avelumab); Merck (Pembrolizumab); Boston Biomedical (BBI-608); Medimmune (MEDI4736/Durvalumab & Tremelimumab); Halozyme (PEGPH20); Aslan Pharmaceuticals (Varlitinib); Janssen (Erdafitinib); Prime Therapeutics (Bemarituzumab); Epizyme (Tazemetostat); Plexikon (PLX3397, ie. Pexidartinib); Five Prime Therapeutics (FPA144, ie. bemarituzumab); Novartis (Panobinostat); QED (Infigratinib); and investigator-led trials with drug supply of Trastuzumab emtansine (T-DM1) by Roche, and of Durvalumab & Tremelimumab by Astra Zeneca<br>2. Member of trial management committee of investigator-led trial with drug supply of Pembrolizumab by Merck.<br>3. Study chair for trial with drug supply by Tilray (TN TC11M)<br>4. Participation in expanded access programs conducted by Merck (Pembrolizumab), Bristol Myers Squibb (Nivolumab), Astra Zeneca (Durvalumab), and Specialised Therapeutics Australia (Trabectedin) | Nil |

|        |        |           |   |   |   |   |     |
|--------|--------|-----------|---|---|---|---|-----|
| Dr     | David  | Gyorki    | Peter MacCallum Cancer Centre, Austin Health, Victorian Comprehensive Cancer Centre – Research & Education Lead, Skin & Melanoma<br>Peter MacCallum Cancer Centre             | Surgical Oncology Committee, Royal Australasian College of Surgeons, Australian Melanoma Guidelines Working Group, NHMRC, International Retroperitoneal Sarcoma Registry – Governance Committee | Society of Surgical Oncology, Connective Tissue Oncology Society, American Society of Clinical Oncology   | Advisory Board – Qbiotics, Amgen, Bayer   | Nil |
| Prof   | Angela | Hong      | Chris O’Brien Lifehouse (Staff Specialist), RPA (HMO), Genesis Cancer Care (VMO)  | University of Sydney (clinical title), Faculty member of Melanoma Institute Australia, Medical Advisory Committee of Cooper Rice Brading Foundation   | Fellow of Royal Australia and New Zealand College of Radiologists, COSA member, Connective Tissue Oncology Society member   | The Limbic: Speaker fee, Q-biotics Paid member of the data safety monitoring board, Uptodate: authorship fee, Bayer: advisory board Fee | Nil |
| Dr     | Anna   | Lawless   | Radiation Oncology Registrar at Chris O’Brien Lifehouse and Royal Prince Alfred Hospital, Sydney Local Health District (with rotations to RNSH and Lismore Hospitals in 2021) | Honorary lecturer at Sydney Medical School  | Trainee member of Royal Australian and New Zealand College of Radiologists (RANZCR), Thoracic Oncology Group of Australasia (TOGA) and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) | Nil   | Nil |
| Ms     | Smaro  | Lazarakis | Melbourne Health  | Nil   | Nil   | Nil   | Nil |
| Dr     | Peter  | Lee       |   |   |   |   |     |
| Dr     | Jeremy | Lewin     | Peter MacCallum Cancer Centre   | Nil   | ANZSA, ANZUP  | Nil   | Nil |
| Dr     | Tracy  | Lim       |   |   |   |   |     |
| Dr     | Helen  | Lo        | Chris O’Brien Lifehouse   | Nil   | Nil   | Nil   | Nil |
| A/Prof | Fiona  | Maclean   | Douglas Hanly Moir Pathology  | President Elect of International Academy of pathology (IAP) Australasian Div, Clinical Associate Professor Macquarie University, Committee member of Global Society of Rare GU tumours          | IAP, ANZSA, Royal Collaegue of Pathologists Australasia, ANZVP member, Australian Institute of Company Directors  | AbbVie March 2020 Speaker for genitourimery meeting   | Nil |

|        |                    |              |  |   |  |                                |     |
|--------|--------------------|--------------|--|---|--|--------------------------------|-----|
| Ms     | Jasmine            | Mar          | Peter MacCallum Cancer Centre - ANZSA  | Nil   | ANZSA  | Nil                            | Nil |
| Dr     | Joshua             | McDonough    | The University of Adelaide   | Nil   | Nil  | Nil                            | Nil |
| Dr     | Wayne              | Nicholls     | Queensland Children's Hospital   | ANZSA & ANZCHOG - Scientific Advisory Committee (SAC)   | SIOP, ANZCHOG, COGNO, COG, SNO, ANZSA                                      | Nil                            | Nil |
| Dr     | Natacha            | Omer         | Queensland Childresn's Hospital  | Nil   | COG, SIOP, ANZCHOG, ASCO, ANZSA, CTOS                                      | Nil                            | Nil |
| Dr     | Lisa               | Orme         | Royal Children's Hospital, PeterMacCallum Cancer Centre  | ANZSA - Scientific Advisory Committee   | ANZSA, RACP, CTOS, COG   | Nil                            | Nil |
| Dr     | Charlotte          | Payne        | Cardiff Medical Centre and Skin Cancer Clinic  | Nil   | RACGP  | Nil                            | Nil |
| Dr     | Ganapathy (Ganaps) | Perianayagam | Tumour and Arthroplasty Fellow, Royal Prince Alfred Hospital   | Nil   | Australian Medical Council, Fellow of Royal College of Surgeons, Edinburgh | Nil                            | Nil |
| A/Prof | Marianne           | Phillips     | Perth Children's Hospital  | ANZSA Board, Children's Oncology Group Principal Investigator, ICPCN Board, PaPCANZ Executive, ANZCHOG Solid Tumour Committee, Redkite Governor | COG, ANZCHOG, SIOP, CCLG, COSA, PCA, PaPCANZ, RCP, RCPCH                   | Nil                            | Nil |
| A/Prof | David              | Pryor        | Fellow of the Royal Australasian College of Surgeons, Member of General Surgeons Australia   | ANZSA Scientific Advisory Committee   | ANZSA FRANZCR  | 24-2-2020 ROCHE Advisory Board |     |
| Ms     | Ashika             | Ramamurthy   | Nil  | Nil   | Nil  | Nil                            | Nil |
| Dr     | Richard            | Smith        |  |   |  |                                |     |
| A/Prof | Peter              | Steadman     | Medhealth Australia, Medilaw group Australia, Queensland Health Princess Alexandra and Queensland Children's Hospitals, Private practice "Steadman Orthopaedics", University of Queensland | Chairman Queensland Orthopaedic research trust institute, International society of Limb Salvage, International skeletal society                 | AOA, AMA, RACS, AAOS   |                                | Nil |

|    |          |            |   |   |   |     |     |
|----|----------|------------|---|---|---|-----|-----|
| Dr | Stephen  | Thompson   | Prince of Wales Hospital  | NSW CI, RANZCR, GOROC, UNSW TCRN/SPHERE, ANZSA SAC  | RANZCR, GITG, TROG, COSA, ANZSA, ALLG   | Nil | Nil |
| Ms | Julijana | Todorovic  | Slater and Gordon Lawyers   | Chair – Banksia Gardens Community Services, Victorian Labor Party – Gender Equality Working Group                     | Law Institute of Victoria, Victorian Women Lawyers, EMILY's List  | Nil | Nil |
| Dr | Elissa   | Tong       | NSW Health - Royal North Shore Hospital   | Nil   | Trans Tasman Radiation Oncology Group member  | Nil | Nil |
| Dr | Cristina | Vargas     | Consultant in Histopathology - Douglass Hanly Moir Pathology, Newcastle Research Affiliate: Kolling Institute of Medical Research, the Faculty of Medicine and Health, The University of Sydney | Research Affiliate and member of the Research/Postgraduate teaching committee (USYD Specialty of Clinical Pathology). | The Royal College of Pathologists of Australasia United States and Canadian Academy of Pathology  | Nil | Nil |
| Ms | Jennifer | Vu         | Nil   | Nil   | Nil   | Nil | Nil |
| Mr | Mark     | Winstanley | Starship Children's Hospital, Auckland District Health Board  | Nil   | RACP, COG, ANZCHOG  | Nil | Nil |
| Dr | Mei      | Zhang      |   | Nil   | Nil   | Nil | Nil |
| Dr | Deborah  | Zhou       | Medical Oncology Fellow (Sarcoma) at Chris O'Brien Lifehouse, Sydney  | Nil   | ANZSA , MOGA – Medical Oncology Group of Australia , ESMO – European Society of Medical Oncology, ASCO – American Society of Clinical Oncology, AGITG – Australasian Gastro-Intestinal Trials Group | Nil | Nil |